TECH
TECH
US09073M1045
Bio-Techne Corp
Loading chart...

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Latest News

Related stocks

PCVX
PCVX • United States
Vaxcyte, Inc.
71.38 USD
10.62B USD 1Y +59.6%
ARWR
ARWR • United States
Arrowhead Pharmaceuticals, Inc.
62.75 USD
8.84B USD 1Y +64.4%
CAI
CAI • United States
Caris Life Sciences, Inc.
29.7 USD
8.39B USD 1Y -16.5%
NUVL
NUVL • United States
Nuvalent, Inc.
123.96 USD
9.79B USD
PTGX
PTGX • United States
Protagonist Therapeutics, Inc.
143.73 USD
9.3B USD 1Y +114.3%
BBIO
BBIO • United States
BridgeBio Pharma, Inc.
65.35 USD
12.78B USD 1Y +17.6%
HALO
HALO • United States
Halozyme Therapeutics, Inc.
110.42 USD
12.53B USD 1Y +68.5%
MANE
MANE • United States
Veradermics, Incorporated
130.9 USD
5.47B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
39.4% p.a.
Max Drawdown (5Y)
-67.0%
Sharpe Ratio (5Y)
-0.31
Beta Factor
1.29
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 62.5 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -67.9% in the extended horizon.
ende